Artelo's ART27.13 Matches Semaglutide Weight Loss, Doubles It in Combo
ARTL is trading near its 52-week low of $4.68 (7.3% above the low).
Summary
Artelo announced nonclinical data showing its oral dual cannabinoid agonist ART27.13 reduced body weight by ~20% in obese mice, matching semaglutide, and ~40% when combined with semaglutide. Weight loss was predominantly fat (~80% for ART27.13 groups vs ~70% for semaglutide alone), with no effect in lean animals. This is the first disclosure of these specific obesity-model results and positions ART27.13 as a potential complementary mechanism to GLP-1s. The company is already in Phase 2 for cancer cachexia and glaucoma, and this data could open partnering discussions in the large metabolic disease market. Given the company's small market cap and going-concern status, this positive data is highly material. Watch for any partnership announcements or initiation of an obesity-focused clinical trial.
At the time of this announcement, ARTL was trading at $5.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $4.68 to $179.19. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.